申请人:Schering Aktiengesellschaft
公开号:US04623649A1
公开(公告)日:1986-11-18
Novel substituted .beta.-carboline derivatives of Formula I ##STR1## wherein R.sup.3 is an oxadiazolyl residue of the formula ##STR2## wherein R.sup.5 stands for lower alkyl of up to 3 carbon atoms or an ester ##STR3## with R.sup.6 being hydrogen or lower alkyl of up to 3 carbon atoms, R.sup.4 is hydrogen, lower alkyl of up to 3 carbon atoms, or CH.sub.2 OR.sup.9 wherein R.sup.9 is lower alkyl of up to 3 carbon atoms, R.sup.A is phenyl or a hydrocarbon residue containing 2-10 carbon atoms which can be cyclic or acyclic, saturated or unsaturated, branched or unbranched, and which can optionally be substituted by oxo, formyl OH, O-alkyl of up to 3 carbon atoms or phenyl, and wherein, in a cyclic hydrocarbon residue, a CH.sub.2 -group can be replaced by oxygen, exhibit an effect on the central nervous system and thus are suitable as psychopharmaceuticals.
化合物I的新型替代.beta.-吲哚啉衍生物,其中R.sup.3是公式##STR2##中的氧代二唑基残基,其中R.sup.5代表最多3个碳原子的低级烷基或酯##STR3##,其中R.sup.6是氢或最多3个碳原子的低级烷基,R.sup.4是氢、最多3个碳原子的低级烷基或CH.sub.2 OR.sup.9,其中R.sup.9是最多3个碳原子的低级烷基,R.sup.A是苯基或含有2-10个碳原子的烃基残基,可以是环状或非环状,饱和或不饱和,支链或直链,可以选择地被氧代、甲酰、OH、最多3个碳原子的O-烷基或苯基取代,在环状烃基残基中,CH.sub.2 -基可以被氧原子替代,在中枢神经系统上表现出作用,因此适用于作为精神药物。